Skip to main content

Table 1 Patient characteristics

From: PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Characteristic

Number of Patients (%) (n=42)

Gender

 
 

Female

23 (55%)

 

Male

19 (45%)

Age (Years)

 
 

Median (range)

60 (27–85)

Ethnicity

 
 

Caucasian

34 (81%)

 

Other

8 (19%)

ECOG performance status

 
 

Median (range)

1 (0–1)

Tumour type

 
 

NSCLC

10 (24%)

 

Gastrointestinal

7 (17%)

 

Genitourinary

4 (10%)

 

Prostate

4 (10%)

 

Head and neck

3 (7%)

 

Melanoma

3 (7%)

 

Sarcoma

3 (7%)

 

Other

8 (19%)

Number of prior chemotherapy regimens

 
 

Median (range)

1 (0–3)